ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC lessened its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 45.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,370 shares of the specialty pharmaceutical company’s stock after selling 6,910 shares during the period. Legato Capital Management LLC’s holdings in ANI Pharmaceuticals were worth $661,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ANIP. Advisors Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth about $28,000. Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares in the last quarter. State of Wyoming acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of ANI Pharmaceuticals by 30.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after acquiring an additional 253 shares in the last quarter. Finally, Federated Hermes Inc. acquired a new stake in shares of ANI Pharmaceuticals during the 3rd quarter worth about $93,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ANIP shares. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Trading Down 1.6%

ANIP opened at $81.41 on Wednesday. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 20.61 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 52 week low of $57.33 and a 52 week high of $99.50. The business’s 50 day moving average is $78.32 and its two-hundred day moving average is $79.85. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm’s revenue was up 20.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total transaction of $357,470.52. Following the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at $2,901,264.30. The trade was a 10.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 55,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $77.57, for a total value of $4,266,350.00. Following the transaction, the chief executive officer directly owned 349,889 shares in the company, valued at approximately $27,140,889.73. This trade represents a 13.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 91,427 shares of company stock valued at $7,089,066 over the last 90 days. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.